MeSH tree: D12.776.124.486.485.114.224
For patients with moderate-to-severe Crohn's disease, risankizumab is noninferior to ustekinumab for clinical remission at week 24 and is superior for endoscopic remission at week 48, according to a study published in the ...
Jul 18, 2024
0
43
A new editorial paper titled "HER2-low and HER2-zero in breast cancer between prognosis, prediction and entity" has been published in Oncotarget.
Jul 16, 2024
0
38
Subcutaneous delivery of an anti-TNF inhibitor drug improved remission rates in patients with moderate-to-severe Crohn's disease and ulcerative colitis, according to recent phase 3 clinical trial results published in the ...
Jul 16, 2024
0
46
A model co-designed by a professor at Anglia Ruskin University is expected to reduce the need for chemotherapy in up to 38% of breast cancer patients who would previously have been advised to consider the treatment.
Jul 12, 2024
0
47
The European Union has approved Sanofi and Regeneron's blockbuster drug Dupixent for the treatment of chronic obstructive pulmonary disease (COPD), the French pharmaceutical giant said on Wednesday.
Jul 3, 2024
0
66
Physician scientists from City of Hope, one of the largest cancer research and treatment organizations in the United States, found that people with metastatic kidney cancer who orally took a live biotherapeutic product called ...
Jun 28, 2024
0
473
A year of treatment with a medicine made of an antibody and chemotherapy drug has proven highly effective in preventing stage 1 HER2-positive breast cancer from recurring in patients, a team led by Dana-Farber Cancer Institute ...
Jun 27, 2024
0
50
A multi-disciplinary task force convened by the American Society for Radiation Oncology has issued new guidelines for radiation therapy for HPV-associated oropharyngeal squamous cell carcinoma (OPSCC).
Jun 18, 2024
0
41
Combining two cancer drugs may be a promising treatment for advanced metastatic breast cancer, according to the results of a clinical trial published in JAMA Oncology.
Jun 17, 2024
0
58
Bisphosphonates are the recommended first-line treatment in post-menopausal osteoporosis, with denosumab recommended second-line. Based on the length of clinical trials for bisphosphonates, these drugs are usually prescribed ...
Jun 12, 2024
0
36
